



# Review High-Resolution Computed Tomography as an Initial Diagnostic and Localization Tool in Patients with Cerebrospinal Fluid Rhinorrhea: A Meta-Analysis

Do Hyun Kim <sup>1</sup><sup>(1)</sup>, Sung Won Kim <sup>1</sup>, Jae Sang Han <sup>1</sup>, Geun-Jeon Kim <sup>1</sup>, Mohammed Abdullah Basurrah <sup>2</sup><sup>(1)</sup> and Se Hwan Hwang <sup>3</sup>,\*<sup>(2)</sup>

- <sup>1</sup> Department of Otolaryngology-Head and Neck Surgery, Seoul Saint Mary's Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero Seocho-gu, Seoul 06591, Republic of Korea
- <sup>2</sup> Department of Surgery, College of Medicine, Taif University, Taif 21944, Saudi Arabia
- <sup>3</sup> Department of Otolaryngology-Head and Neck Surgery, Bucheon Saint Mary's Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero Seocho-gu, Seoul 06591, Republic of Korea
- \* Correspondence: yellobird@catholic.ac.kr; Tel.: +82-32-340-7044; Fax: +82-32-340-2674

**Abstract:** *Background and Objectives*: This study was performed to investigate the utility of highresolution computed tomography (HRCT) for the initial localization of cerebrospinal fluid rhinorrhea. *Methods*: HRCT data regarding the point of cerebrospinal fluid leakage (as confirmed in the operating room), collected up to December 2022, were extracted from five databases. The risk of bias of the included studies was assessed using the Quality Assessment of Diagnostic Accuracy Studies 2 tool. *Results*: The search revealed eight relevant studies with a total of 254 patients. The diagnostic odds ratio of the imaging studies was 10.0729 (95% confidence interval [CI]: 2.4486; 41.4376; I<sup>2</sup> = 54.1%). The area under the summary receiver operating characteristic curve was 0.8. Sensitivity, specificity, the negative predictive value, and the positive predictive value were 0.7550 (95% CI: 0.6163; 0.8553; I<sup>2</sup> = 69.8%), 0.8502 (95% CI: 0.5986; 0.9557, I<sup>2</sup> = 49.3%), 0.4106 (95% CI: 0.2418; 0.6035; I<sup>2</sup> = 59.0%), and 0.9575 (95% CI: 0.8955; 0.9834; I<sup>2</sup> = 27.7%), respectively. *Conclusions*: HRCT can be used to accurately localize cerebrospinal fluid rhinorrhea because it shows bony defects in high detail. However, it has limited utility for the evaluation of active leakage, and localization is difficult in the presence of coexisting lesions.

**Keywords:** cerebrospinal fluid; cerebrospinal fluid leak; outcome assessment; health care; diagnosis; meta-analysis

# 1. Introduction

Cerebrospinal fluid (CSF) rhinorrhea can occur spontaneously, as a result of trauma, and after surgery. If the fistula persists, free communication between the nasal cavity and intracranial space can provide an open channel for the transmission of infection [1]. Meningitis occurs in 10–25% of patients with unresolved CSF leaks, 10% of whom die [2,3].  $\beta$ 2-Transferrin and  $\beta$ -trace protein measurement, along with radionuclide cisternography, are representative methods to confirm CSF rhinorrhea. Failure to precisely determine the leakage point may result in repair failure despite surgery. In addition, standard nasal endoscopy has limitations in determining the location of CSF leaks. In order to compensate for this point, intrathecal fluorescein is administered to help confirm the leak point with an endoscope. Therefore, radiological assessments play a crucial role in localizing leakage points in cases of CSF rhinorrhea. Various methods for the localization of CSF rhinorrhea are available, including high-resolution computed tomography (HRCT), cisternography with magnetic resonance imaging (MRI), computed tomography (CT), and radionuclide cisternography. HRCT may be useful as an initial diagnostic modality because it can be



Citation: Kim, D.H.; Kim, S.W.; Han, J.S.; Kim, G.-J.; Basurrah, M.A.; Hwang, S.H. High-Resolution Computed Tomography as an Initial Diagnostic and Localization Tool in Patients with Cerebrospinal Fluid Rhinorrhea: A Meta-Analysis. *Medicina* 2023, *59*, 540. https:// doi.org/10.3390/medicina59030540

Academic Editor: Silviu Albu

Received: 31 January 2023 Revised: 7 March 2023 Accepted: 9 March 2023 Published: 10 March 2023



**Copyright:** © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). used to localize bony defects, can be performed rapidly, poses little risk, and is relatively inexpensive [4–6]. However, the diagnostic power of HRCT for CSF rhinorrhea differs among studies. In addition, there have been no reviews of the diagnostic accuracy, sensitivity, and specificity of HRCT for CSF rhinorrhea. Therefore, this meta-analysis was performed to confirm the diagnostic utility of HRCT for CSF rhinorrhea, and to discuss its clinical applications and provide information that will be useful for patients.

#### 2. Materials and Methods

#### 2.1. Study Protocol

This systematic review and meta-analysis was conducted in accordance with the Preferred Reporting Items Guidelines for Systematic Review and Meta-Analysis (PRISMA) [7]. The research protocol is prospectively registered in the Open Science Framework "https: //osf.io/q7pxw/ (accessed on 10 August 2021)".

#### 2.2. Literature Search Strategy

Studies were identified in the PubMed, SCOPUS, Embase, Web of Science, and Cochrane Central Register of Controlled Trials databases up to December 2022. The search terms were as follows: "cerebrospinal fluid rhinorrhea", "cerebrospinal fluid", "CSF leak", "CSF rhinorrhea", "cerebrospinal fluid fistula", "CSF fistula", "diagnosis", "localization", "imaging", and "computed tomography". Two independent reviewers checked the summaries and titles of all articles retrieved from the databases, and excluded articles unrelated to the topic of interest. In cases where the two reviewers did not agree, a decision on study inclusion was reached through discussion with a third reviewer.

#### 2.3. Study Inclusion Criteria

The study inclusion criteria were as follows: the enrolment of patients who underwent HRCT for the assessment of CSF rhinorrhea; cohort studies; a comparison of imaging findings and surgical results; and inclusion of data allowing sensitivity and specificity to be determined. Case reports and review articles, as well as reports that did not include data allowing sensitivity and specificity values to be derived, were excluded.

#### 2.4. Data Curation and Risk of Bias Assessment

Study data were standardized for analysis purposes [8–10], and included diagnostic odds ratio (DOR), summary receiver operating characteristic (sROC) curve, and area under the curve (AUC) values. The DOR was calculated as follows: (true-positive (TP)/falsepositive (FP))/(false-negative (FN)/true-negative (TN)). The DOR was used as a proxy of diagnostic accuracy, and was calculated along with 95% confidence intervals (CIs) using random-effects models that considered both within- and between-study differences [2,11–17]. The DOR was obtained in the context of a surgical identification of CSF leakage and ranged from 0 to infinity; higher values indicate a better diagnostic performance. A DOR of 1 indicates that the diagnostic method is of no assistance with respect to determining the presence or absence of disease, and values of 0–1 indicate an inverse correlation. The sROC curve is the most intuitive method for calculating sensitivity and specificity values for meta-analyses. As the discriminant power of the test increases, the sROC curve moves closer to the upper left corner of the ROC space, where both sensitivity and specificity are 1 (100%) [18]. The AUC has a value of 0–1, with higher values indicating greater accuracy of the diagnostic test. An AUC of 0.90–1.0 is considered to indicate excellent diagnostic accuracy, while a value of 0.80-0.90 is good, 0.70-0.80 is fair, 0.60-0.70 is poor, and 0.50–0.60 indicates diagnostic failure [19]. The Quality Assessment of Diagnostic Accuracy Studies 2 tool was used to evaluate risk of bias [20].

#### 2.5. Statistical Analysis

R software (version 4.2.2; R Foundation for Statistical Computing, Vienna, Austria) was used for the meta-analysis. Heterogeneity was evaluated using the Q statistic. Forest

plots of sensitivity and specificity (based on sROC curves) are presented. Egger's test and Begg's funnel plot test were not performed due to the small number of included studies (<10).

# 3. Results

Eight studies with a total of 254 patients were included in the analysis (Figure 1). The characteristics of the included studies and bias evaluation results are shown in Tables 1 and 2.



Figure 1. Flow diagram of the selection of studies.

The DOR of HRCT was 10.0729 (95% confidence interval [CI]: 2.4486; 41.4376;  $I^2 = 54.1\%$ ) (Figure 2). The AUC was 0.8, which indicates good diagnostic accuracy (Figure 3). The sensitivity, specificity, negative predictive value, and positive predictive value were 0.7550 (95% CI: 0.6163; 0.8553;  $I^2 = 69.8\%$ ), 0.8502 (95% CI: 0.5986; 0.9557,  $I^2 = 49.3\%$ ), 0.4106 (95% CI: 0.2418; 0.6035;  $I^2 = 59.0\%$ ), and 0.9575 (95% CI: 0.8955; 0.9834;  $I^2 = 27.7\%$ ), respectively (Figure 4).

Study	Experim Events	ental Total Ev	Cor vents 1	ntrol Fotal	Odds Ratio	OR	95%-CI Weight
g = CT Eljamel 1995 Shetty 1998 Chan 2004 Algin 2010 Tahir 2011 Ragheb 2014 Bhatia 2020 Hablas 2022 Random effects model Heterogeneity: $l^2 = 54\%$ , $\tau$	7 35 12 8 12 15 31 28 <sup>2</sup> = 2.2393,		8 3 2 12 8 3 10	12 10 6 8 13 9 6 20 84		3.500 [0.31 152.143 [7.990 25.000 [1.02 24.000 [1.74 0.500 [0.0 0.938 [0.07 31.000 [2.40 57.000 [3.062 10.073 [2.44	3; 39.153]       13.9%         ; 3264.643]       11.1%         8; 608.092]       10.6%         1; 330.804]       12.9%         40; 6.279]       13.3%         '3; 11.997]       13.2%         9; 398.879]       13.2%         1061.023]       11.7%         9; 41.438]       100.0%
Random effects model Heterogeneity: $I^2 = 54\%$ , $\tau$ Residual heterogeneity: $I^2$	<sup>2</sup> = 2.2393, = 54%, p =	<b>155</b> <i>p</i> = 0.03 = 0.03	\$	<b>84</b> 0.001	0.1 1 10 1000	10.073 [2.44	9; 41.438] 100.0%

Figure 2. Diagnostic accuracy of included studies [2,11–17].

Study	Design	Number of Patients	Sex (Male/Female)	Age, Median (Range) or Mean (SD), y	Nation	Frequency of Radiologic Exam/Numbers of Lesion	TP	FN	FP	TN
Eljamel 1995 [11]	Case series	21	16/5	33 ± 14 (2–60)	Ireland	21	7	8	1	4
Shetty 1998 [2]	Cohort	45	28/17	3–62	India	45	35	3	0	7
Chan 2004 [12]	Cohort	18	NA	NA	China	18	12	3	0	3
Algin 2010 [13]	Cohort	17	13/4	32 (11–70)	Turkey	17	8	2	1	6
Tahir 2011 [15]	Cohort	43	17/26	40.6 (3–74)	Pakistan	43	12	12	2	1
Ragheb 2014 [14]	Cohort	24	16/8	33–62	Egypt	24	15	8	2	1
Bhatia 2020 [16]	Cohort	38	21/17	NR	India	38	31	3	1	3
Hablas 2022 [17]	Case series	48	20/28	19–67	Egypt	48	28	10	0	10

Table 1. Characteristics of the included studies.

Abbreviations: NR, not reported; TP, true positive; TN, true negative; FP, false positive; FN, false negative.

 Table 2. Methodological quality of the included studies.

		Risk	of Bias		<b>Concerns about Application</b>			
Reference	Patient Selection	Index Test	Reference Standard	Flow and Timing	Patient Selection	Index Test	Reference Standard	
Eljamel 1995 [11]	Low	Low	Unclear	Low	Low	Low	Low	
Shetty 1998 [2]	Low	Low	Low	Low	Low	Low	Low	
Chan 2004 [12]	Low	Low	Unclear	Low	Low	Low	Low	
Algin 2010 [ <mark>13</mark> ]	Low	Low	Unclear	Low	Low	Low	Low	
Tahir 2011 [15]	Unclear	Low	Unclear	Unclear	Low	Low	Low	
Ragheb 2014 [14]	Low	Low	Unclear	Low	Low	Low	Low	
Bhatia 2020 [16]	Low	Low	Low	Low	Low	Low	Low	
Hablas 2022 [17]	Low	Low	Low	Low	Low	Low	Low	



**Figure 3.** The summary receiver operating characteristic curve. Thick curved line (summary receiver operating characteristic curve), thin circular line (95% confidence region), and small circle (summary estimate).

Α	Study	Events Total		Proportion	95%-CI
	a = CT		1		
	Eliamel 1995	7 15		0.467	[0 213: 0 734]
	Shothy 1008	35 39		0.407	[0.213, 0.734]
	Chan 2004	12 15		0.921	[0.700, 0.903]
	Aloin 2010	8 10		0.000	[0.313, 0.337]
	Tabir 2011	12 24		0.000	[0.444, 0.375]
	Ranheb 2014	15 23		0.652	[0.427: 0.836]
	Bhatia 2020	31 34		0.002	[0.763: 0.081]
	Hablas 2020	28 38		0.312	[0.569; 0.866]
	Random effects model	197		0.755	[0.616: 0.855]
	Heterogeneity: $I^2 = 70\%$ , $\tau^2$	$p^2 = 0.6013, p < 0$	.01	0.100	[0.010, 0.000]
	Random effects model	197		0.755	[0.616: 0.855]
	Heterogeneity: $I^2 = 70\%$ , $\tau$	$^{2} = 0.6013, p < 0$	.01		,
	Residual heterogeneity: 12	= 69%, <i>p</i> < 0.01	0.3 0.4 0.5 0.6 0.7 0.8 0.9		
D	Ohada	<b>E</b>		Descrition	05% 01
В	Study	Events Total		Proportion	95%-CI
	g = CT		1		
	Eliamel 1995	4 5		0.800	[0.284: 0.995]
	Shetty 1998	7 7		1.000	[0.590: 1.000]
	Chan 2004	3 3		1.000	[0.292; 1.000]
	Algin 2010	6 7	i	0.857	[0.421: 0.996]
	Tahir 2011	1 3		0.333	[0.008: 0.906]
	Ragheb 2014	1 3		0.333	[0.008; 0.906]
	Bhatia 2020	3 4		0.750	[0.194: 0.994]
	Hablas 2022	10 10		1.000	[0.692; 1.000]
	Random effects model	42	>	0.850	[0.599; 0.956]
	Heterogeneity: $I^2 = 49\%$ , $\tau^2$	<sup>2</sup> = 1.5281, <i>p</i> = 0	.77		- / -
	Random effects model	42		0 850	10 599 0 9561
	Heterogeneity: $I^2 = 49\%$ $\tau^2$	$^{2} = 1.5281$ $n = 0$	77	0.000	[0.000, 0.000]
	Residual heterogeneity: $I^2$	= 0% p = 0.77	0.2 0.4 0.6 0.8 1		
	i toolaaa notologonoliyi i	o,p o			
С	Study	Events Total		Proportion	95%-CI
С	Study	Events Total	ł	Proportion	95%-CI
С	Study g = CT Fliamel 1995	Events Total		Proportion	<b>95%-CI</b>
С	Study g = CT Eljamel 1995 Shetty 1998	Events Total 4 12 7 10	<u>_</u>	Proportion 0.333 0.700	<b>95%-CI</b> [0.099; 0.651] [0.348: 0.933]
С	Study g = CT Eljamel 1995 Shetty 1998 Chan 2004	Events Total 4 12 7 10 3 6		Proportion 0.333 0.700 0.500	<b>95%-Cl</b> [0.099; 0.651] [0.348; 0.933] [0.118: 0.882]
С	Study g = CT Eljamel 1995 Shetty 1998 Chan 2004 Algin 2010	Events Total 4 12 7 10 3 6 6 8		Proportion 0.333 0.700 0.500 0.750	<b>95%-Cl</b> [0.099; 0.651] [0.348; 0.933] [0.118; 0.882] [0.349: 0.968]
С	<b>Study</b> g = CT Eljamel 1995 Shetty 1998 Chan 2004 Algin 2010 Tabir 2011	Events Total 4 12 7 10 3 6 6 8 1 13		Proportion 0.333 0.700 0.500 0.750 0.077	<b>95%-Cl</b> [0.099; 0.651] [0.348; 0.933] [0.118; 0.882] [0.349; 0.968] [0 002; 0.360]
С	Study g = CT Eljamel 1995 Shetty 1998 Chan 2004 Algin 2010 Tahir 2011 Radheb 2014	Events Total 4 12 7 10 3 6 6 8 1 13 1 9		Proportion 0.333 0.700 0.500 0.750 0.077 0.111	<b>95%-Cl</b> [0.099; 0.651] [0.348; 0.933] [0.118; 0.882] [0.349; 0.968] [0.002; 0.360] [0.003; 0.482]
С	Study g = CT Eljamel 1995 Shetty 1998 Chan 2004 Algin 2010 Tahir 2011 Ragheb 2014 Bhatia 2020	Events Total 4 12 7 10 3 6 6 8 1 13 1 9 3 6		Proportion 0.333 0.700 0.500 0.750 0.077 0.111 0.500	<b>95%-Cl</b> [0.099; 0.651] [0.348; 0.933] [0.118; 0.882] [0.349; 0.968] [0.002; 0.360] [0.003; 0.482] [0.118; 0.882]
C	Study g = CT Eljamel 1995 Shetty 1998 Chan 2004 Algin 2010 Tahir 2011 Ragheb 2014 Bhatia 2020 Hablas 2022	Events Total 4 12 7 10 3 6 6 8 1 13 1 9 3 6 10 20		Proportion 0.333 0.700 0.500 0.750 0.077 0.111 0.500 0.500	<b>95%-Cl</b> [0.099; 0.651] [0.348; 0.933] [0.118; 0.882] [0.349; 0.968] [0.002; 0.360] [0.003; 0.482] [0.118; 0.882] [0.272; 0.728]
С	Study g = CT Eljamel 1995 Shetty 1998 Chan 2004 Algin 2010 Tahir 2011 Ragheb 2014 Bhatia 2020 Hablas 2022 Random effects model	Events Total 4 12 7 10 3 6 6 8 1 13 1 9 3 6 10 20 84		Proportion 0.333 0.700 0.500 0.750 0.077 0.111 0.500 0.500 0.411	<b>95%-Cl</b> [0.099; 0.651] [0.348; 0.933] [0.118; 0.882] [0.349; 0.968] [0.002; 0.360] [0.002; 0.360] [0.003; 0.482] [0.118; 0.882] [0.272; 0.728] [0.242; 0.603]
С	Study g = CT Eljamel 1995 Shetty 1998 Chan 2004 Algin 2010 Tahir 2011 Ragheb 2014 Bhatia 2020 Hablas 2022 Random effects model Heterogeneity: $l^2 = 59\%$ , $\tau^2$	Events Total 4 12 7 10 3 6 6 8 1 13 1 9 3 6 10 20 84 <sup>2</sup> = 0.7598, <i>p</i> = 0		Proportion 0.333 0.700 0.500 0.750 0.077 0.111 0.500 0.500 0.411	<b>95%-Cl</b> [0.099; 0.651] [0.348; 0.933] [0.118; 0.882] [0.349; 0.968] [0.002; 0.360] [0.003; 0.482] [0.003; 0.482] [0.272; 0.728] [0.272; 0.728]
C	Study g = CT Eljamel 1995 Shetty 1998 Chan 2004 Algin 2010 Tahir 2011 Ragheb 2014 Bhatia 2020 Hablas 2022 Random effects model Heterogeneity: $I^2 = 59\%$ , $\tau^2$ Random effects model	Events Total 4 12 7 10 3 6 6 8 1 13 1 9 3 6 10 20 84 <sup>2</sup> = 0.7598, p = 0 84		Proportion 0.333 0.700 0.500 0.750 0.077 0.111 0.500 0.500 0.411	95%-Cl [0.099; 0.651] [0.348; 0.933] [0.118; 0.882] [0.349; 0.968] [0.002; 0.360] [0.002; 0.360] [0.002; 0.360] [0.022; 0.728] [0.272; 0.603]
С	Study g = CT Eljamel 1995 Shetty 1998 Chan 2004 Algin 2010 Tahir 2011 Ragheb 2014 Bhatia 2020 Random effects model Heterogeneity: $l^2 = 59\%$ , $\tau^2$ Random effects model Heterogeneity: $l^2 = 59\%$ , $\tau^2$	Events Total 4 12 7 10 3 6 6 8 1 13 1 9 3 6 10 20 $^2 = 0.7598, p = 0$ $^2 = 0.7598, p = 0$		Proportion 0.333 0.700 0.500 0.770 0.111 0.500 0.411 0.411	95%-Cl [0.099; 0.651] [0.348; 0.933] [0.118; 0.882] [0.349; 0.968] [0.002; 0.360] [0.003; 0.482] [0.003; 0.482] [0.272; 0.728] [0.242; 0.603]
С	Study g = CT Eljamel 1995 Shetty 1998 Chan 2004 Algin 2010 Tahir 2011 Ragheb 2014 Bhatia 2020 Random effects model Heterogeneity: $J^2 = 59\%, z'$ Random effects model Heterogeneity: $J^2$	Events Total 4 12 7 10 3 6 8 1 13 1 9 3 6 10 20 $^2 = 0.7598, p = 0$ 84 $^2 = 0.7598, p = 0$ 84		Proportion 0.333 0.700 0.500 0.750 0.077 0.111 0.500 0.500 0.411 0.411	95%-Cl [0.099; 0.651] [0.348; 0.933] [0.118; 0.882] [0.349; 0.968] [0.002; 0.360] [0.003; 0.482] [0.118; 0.882] [0.272; 0.728] [0.242; 0.603]
C	Study g = CT Eljamel 1995 Shetty 1998 Chan 2004 Algin 2010 Tahir 2011 Ragheb 2014 Bhatia 2020 Hablas 2022 Random effects model Heterogeneity: $l^2 = 59\%$ , $\tau^2$ Random effects model Heterogeneity: $l^2$ Study	Events Total 4 12 7 10 3 6 6 8 1 13 1 9 3 6 10 20 $^2 = 0.7598, p = 0$ 84 $^2 = 0.7598, p = 0$ 84 $^2 = 0.7598, p = 0$ Events Total		Proportion 0.333 0.700 0.500 0.750 0.077 0.111 0.500 0.500 0.411 0.411 Proportion	95%-Cl [0.099; 0.651] [0.348; 0.933] [0.118; 0.882] [0.349; 0.968] [0.002; 0.360] [0.003; 0.482] [0.003; 0.482] [0.272; 0.728] [0.242; 0.603] [0.242; 0.603]
C	Study g = CT Eljamel 1995 Shetty 1998 Chan 2004 Algin 2010 Tahir 2011 Ragheb 2014 Bhatia 2020 Random effects model Heterogeneity: $I^2 = 59\%, \tau^2$ Random effects model Heterogeneity: $I^2$ Rasidual heterogeneity: $I^2$	Events Total 4 12 7 10 3 6 8 1 13 1 9 3 6 10 20 84 $^2 = 0.7598, p = 0$ 84 $^2 = 0.7598, p = 0.06$ Events Total		Proportion 0.333 0.700 0.500 0.750 0.077 0.111 0.500 0.500 0.411 0.411 Proportion	95%-Cl [0.099; 0.651] [0.348; 0.933] [0.118; 0.882] [0.349; 0.968] [0.002; 0.360] [0.003; 0.482] [0.118; 0.882] [0.272; 0.728] [0.242; 0.603] [0.242; 0.603]
C	Study g = CT Eljamel 1995 Shetty 1998 Chan 2004 Algin 2010 Tahir 2011 Ragheb 2014 Bhatia 2020 Hablas 2022 Random effects model Heterogeneity: $l^2 = 59\%$ , $\tau^2$ Residual heterogeneity: $l^2$ Study g = CT	Events Total 4 12 7 10 3 6 6 8 1 13 1 9 3 6 10 20 $^{2}$ = 0.7598, $p$ = 0 $^{2}$ = 0.7598, $p$ = 0 = 49%, $p$ = 0.06 Events Total		Proportion 0.333 0.700 0.500 0.770 0.111 0.500 0.411 0.411 Proportion	95%-Cl [0.099; 0.651] [0.348; 0.933] [0.118; 0.882] [0.349; 0.968] [0.002; 0.360] [0.002; 0.360] [0.002; 0.360] [0.272; 0.728] [0.272; 0.603] [0.242; 0.603]
C D	Study g = CT Eljamel 1995 Shetty 1998 Chan 2004 Algin 2010 Tahir 2011 Ragheb 2014 Bhatia 2020 Random effects model Heterogeneity: $l^2 = 59\%, \tau^2$ Random effects model Heterogeneity: $l^2$ Study g = CT Eljamel 1995	Events Total 4 12 7 10 3 6 6 8 1 13 1 9 3 6 10 20 84 $^2 = 0.7598, p = 0$ $^2 = 0.7598, p = 0.06$ Events Total 7 8		Proportion 0.333 0.700 0.500 0.750 0.077 0.111 0.500 0.411 0.411 Proportion 0.875	95%-Cl [0.099; 0.651] [0.348; 0.933] [0.118; 0.882] [0.349; 0.968] [0.002; 0.360] [0.003; 0.482] [0.003; 0.482] [0.272; 0.728] [0.272; 0.728] [0.242; 0.603] [0.242; 0.603] 95%-Cl [0.473; 0.997]
C D	Study g = CT Eljamel 1995 Shetty 1998 Chan 2004 Algin 2010 Tahir 2011 Ragheb 2014 Bhatia 2020 Hablas 2022 Random effects model Heterogeneity: $l^2 = 59\%$ , $\tau^2$ Random effects model Heterogeneity: $l^2$ Study g = CT Eljamel 1995 Shetty 1998	Events Total 4 12 7 10 3 6 6 8 1 13 1 9 3 6 10 20 $^2 = 0.7598, p = 0$ = 49%, p = 0.06 Events Total 7 8 35 35		Proportion 0.333 0.700 0.500 0.750 0.077 0.111 0.500 0.500 0.411 0.411 Proportion 0.875 1.000	95%-Cl [0.099; 0.651] [0.348; 0.933] [0.118; 0.882] [0.002; 0.360] [0.002; 0.360] [0.003; 0.482] [0.118; 0.882] [0.272; 0.728] [0.242; 0.603] [0.242; 0.603] 95%-Cl [0.473; 0.997] [0.900; 1.000]
C D	Study g = CT Eljamel 1995 Shetty 1998 Chan 2004 Algin 2010 Tahir 2011 Ragheb 2014 Bhatia 2020 Random effects model Heterogeneity: $I^2 = 59\%, \tau^2$ Random effects model Heterogeneity: $I^2$ Study g = CT Eljamel 1995 Shetty 1998 Chan 2004	Events Total 4 12 7 10 3 6 8 1 13 1 9 3 6 10 20 $^2 = 0.7598, p = 0$ $^2 = 0.7598, p = 0$ Events Total 7 8 35 35 12 12		Proportion 0.333 0.700 0.500 0.750 0.077 0.111 0.500 0.500 0.411 0.411 Proportion 0.875 1.000 1.000	95%-Cl [0.099; 0.651] [0.348; 0.933] [0.118; 0.882] [0.002; 0.360] [0.002; 0.360] [0.003; 0.482] [0.118; 0.882] [0.272; 0.728] [0.242; 0.603] [0.242; 0.603] 95%-Cl [0.473; 0.997] [0.900; 1.000] [0.735; 1.000]
C D	Study g = CT Eljamel 1995 Shetty 1998 Chan 2004 Algin 2010 Tahir 2011 Ragheb 2014 Bhatia 2020 Hablas 2022 Random effects model Heterogeneity: $I^2 = 59\%$ , $\tau^2$ Residual heterogeneity: $I^2$ Study g = CT Eljamel 1995 Shetty 1998 Chan 2004 Algin 2010	Events Total 4 12 7 10 3 6 6 8 1 13 1 9 3 6 10 20 $^2 = 0.7598, p = 0$ $^2 = 0.7598, p = 0.06$ Events Total 7 8 35 35 12 12 8 9		Proportion 0.333 0.700 0.500 0.750 0.077 0.111 0.500 0.500 0.411 0.411 Proportion 0.875 1.000 0.889	95%-Cl [0.099; 0.651] [0.348; 0.933] [0.118; 0.882] [0.349; 0.968] [0.002; 0.360] [0.002; 0.360] [0.0272; 0.3603] [0.272; 0.603] [0.242; 0.603] [0.242; 0.603] [0.242; 0.603] [0.242; 0.603] [0.242; 0.603] [0.242; 0.603]
C D	Study g = CT Eljamel 1995 Shetty 1998 Chan 2004 Algin 2010 Tahir 2011 Ragheb 2014 Bhatia 2020 Random effects model Heterogeneity: $l^2 = 59\%$ , $\tau^2$ Residual heterogeneity: $l^2$ Study g = CT Eljamel 1995 Shetty 1998 Chan 2004 Algin 2010 Tahir 2011	Events Total 4 12 7 10 3 6 6 8 1 13 1 9 3 6 10 20 84 $^2 = 0.7598, p = 0$ $^2 = 0.7598, p = 0.06$ Events Total 7 8 35 35 12 12 8 9 12 14		Proportion 0.333 0.700 0.500 0.770 0.111 0.500 0.411 Proportion 0.875 1.000 0.889 0.857	95%-Cl [0.099; 0.651] [0.348; 0.933] [0.118; 0.882] [0.349; 0.968] [0.002; 0.360] [0.003; 0.482] [0.272; 0.728] [0.272; 0.728] [0.242; 0.603] [0.242; 0.603] 95%-Cl [0.473; 0.997] [0.900; 1.000] [0.578; 0.997] [0.572; 0.882]
C D	Study g = CT Eljamel 1995 Shetty 1998 Chan 2004 Algin 2010 Tahir 2011 Ragheb 2014 Bhatia 2020 Hablas 2022 Random effects model Heterogeneity: $l^2 = 59\%$ , $\tau^2$ Random effects model Heterogeneity: $l^2$ Study g = CT Eljamel 1995 Shetty 1998 Chan 2004 Algin 2010 Tahir 2011 Ragheb 2014	Events Total 4 12 7 10 3 6 6 8 1 13 1 9 3 6 10 20 $^2 = 0.7598, p = 0$ = 49%, p = 0.06 Events Total 7 8 35 35 12 12 8 9 12 14 15 17		Proportion 0.333 0.700 0.500 0.750 0.077 0.111 0.500 0.500 0.411 0.411 Proportion 0.875 1.000 0.882	95%-Cl [0.099; 0.651] [0.348; 0.933] [0.118; 0.882] [0.349; 0.968] [0.002; 0.360] [0.003; 0.482] [0.272; 0.728] [0.272; 0.728] [0.272; 0.603] [0.242; 0.603] [0.242; 0.603] [0.242; 0.603] [0.242; 0.603] [0.242; 0.603] [0.242; 0.603] [0.242; 0.603] [0.242; 0.603] [0.242; 0.603]
C D	Study g = CT Eljamel 1995 Shetty 1998 Chan 2004 Algin 2010 Tahir 2011 Ragheb 2014 Bhatia 2020 Hablas 2022 Random effects model Heterogeneity: $I^2 = 59\%, \tau$ Residual heterogeneity: $I^2$ Study g = CT Eljamel 1995 Shetty 1998 Chan 2004 Algin 2010 Tahir 2011 Ragheb 2014 Bhatia 2020	Events Total 4 12 7 10 3 6 8 1 13 1 9 3 6 10 20 84 2 = 0.7598, p = 0 84 2 = 0.7598, p = 0 Events Total 7 8 35 35 12 12 8 9 12 14 15 17 31 32		Proportion 0.333 0.700 0.500 0.750 0.077 0.111 0.500 0.500 0.411 0.411 Proportion 0.875 1.000 1.000 0.889 0.857 0.882 0.969	95%-Cl [0.099; 0.651] [0.348; 0.933] [0.118; 0.882] [0.002; 0.360] [0.002; 0.360] [0.003; 0.482] [0.118; 0.882] [0.272; 0.728] [0.242; 0.603] [0.242; 0.603] [0.242; 0.603] [0.242; 0.603] [0.242; 0.603] [0.242; 0.603] [0.242; 0.603] [0.242; 0.603] [0.242; 0.603] [0.2518; 0.997] [0.572; 0.982] [0.636; 0.985] [0.838; 0.999]
C D	Study g = CT Eljamel 1995 Shetty 1998 Chan 2004 Algin 2010 Tahir 2011 Ragheb 2014 Bhatia 2020 Hablas 2022 Random effects model Heterogeneity: $I^2 = 59\%$ , $\tau^2$ Residual heterogeneity: $I^2$ Study g = CT Eljamel 1995 Shetty 1998 Chan 2004 Algin 2010 Tahir 2011 Ragheb 2014 Bhatia 2020 Hablas 2022	Events Total 4 12 7 10 3 6 6 8 1 13 1 9 3 6 10 20 $^2$ = 0.7598, p = 0 = 49%, p = 0.06 Events Total 7 8 35 35 12 12 8 9 12 14 15 17 31 32 28 28		Proportion 0.333 0.700 0.500 0.770 0.111 0.500 0.411 0.411 Proportion 0.875 1.000 0.889 0.857 0.882 0.969 1.000	95%-Cl [0.099; 0.651] [0.348; 0.933] [0.118; 0.882] [0.002; 0.360] [0.002; 0.360] [0.002; 0.360] [0.272; 0.728] [0.272; 0.728] [0.242; 0.603] [0.242; 0.603] [0.242; 0.603] [0.242; 0.603] [0.242; 0.603] [0.242; 0.603] [0.242; 0.603] [0.272; 0.987] [0.572; 0.982] [0.838; 0.999] [0.877; 1.000]
C	Study g = CT Eljamel 1995 Shetty 1998 Chan 2004 Algin 2010 Tahir 2011 Ragheb 2014 Bhatia 2020 Random effects model Heterogeneity: $l^2 = 59\%$ , $\tau^2$ Residual heterogeneity: $l^2$ Study g = CT Eljamel 1995 Shetty 1998 Chan 2010 Tahir 2011 Ragheb 2014 Bhatia 2020 Ragheb 2014 Bhatia 2020 Raghebb 2014 Bhatia 2020 Raghebb 2014 Bhatia 2020 Raghebb 2014 Bhatia 2020 Raghebbb 2014	Events Total 4 12 7 10 3 6 6 8 1 13 1 9 3 6 10 20 $^2 = 0.7598, p = 0$ $^2 = 0.7598, p = 0$ $^2 = 0.7598, p = 0.06$ Events Total 7 8 35 35 12 12 8 9 12 14 15 17 31 32 28 28 28 28 155		Proportion 0.333 0.700 0.500 0.750 0.077 0.111 0.500 0.411 0.411 Proportion 0.875 1.000 0.889 0.857 0.882 0.889 1.000 0.957	95%-Cl [0.099; 0.651] [0.348; 0.933] [0.118; 0.882] [0.349; 0.968] [0.002; 0.360] [0.003; 0.482] [0.272; 0.728] [0.272; 0.728] [0.242; 0.603] [0.242; 0.603] [0.2518; 0.997] [0.572; 0.982] [0.636; 0.985] [0.885; 0.983]
C	Study g = CT Eljamel 1995 Shetty 1998 Chan 2004 Algin 2010 Tahir 2011 Ragheb 2014 Bhatia 2020 Hablas 2022 Random effects model Heterogeneity: $I^2 = 59\%, \tau^2$ Residual heterogeneity: $I^2$ Study g = CT Eljamel 1995 Shetty 1998 Chan 2010 Tahir 2011 Ragheb 2014 Bhatia 2020 Hablas 2022 Random effects model Hablas 2021 Hablas 2021 Hablas 2021 Ragheb 2014 Bhatia 2020 Hablas 2022 Random effects model Heterogeneity: $I^2 = 28\%, \tau^2$	Events Total 4 12 7 10 3 6 6 8 1 13 1 9 3 6 10 20 $^2 = 0.7598, p = 0$ $^2 = 0.7598, p = 0$ $^2 = 0.7598, p = 0.06$ Events Total 7 8 35 35 12 12 8 9 12 14 15 17 31 32 28 28 $^2 = 0.4148, p = 0$		Proportion 0.333 0.700 0.500 0.750 0.077 0.111 0.500 0.411 0.411 Proportion 0.875 1.000 0.889 0.857 0.882 0.969 1.000 0.957	95%-Cl [0.099; 0.651] [0.348; 0.933] [0.118; 0.882] [0.002; 0.360] [0.002; 0.360] [0.003; 0.482] [0.118; 0.882] [0.272; 0.728] [0.272; 0.728] [0.242; 0.603] [0.242; 0.603] [0.2518; 0.997] [0.572; 0.982] [0.875; 0.983]
C	Study g = CT Eljamel 1995 Shetty 1998 Chan 2004 Algin 2010 Tahir 2011 Ragheb 2014 Bhatia 2020 Hablas 2022 Random effects model Heterogeneity: $I^2 = 59\%$ , $\tau^2$ Residual heterogeneity: $I^2$ Study g = CT Eljamel 1995 Shetty 1998 Chan 2004 Algin 2010 Tahir 2011 Ragheb 2014 Bhatia 2020 Hablas 2022 Random effects model Heterogeneity: $I^2 = 28\%$ , $\tau^2$ Residual heterogeneity: $I^2$	Events Total 4 12 7 10 3 6 6 8 1 13 1 9 3 6 10 20 $^2 = 0.7598, p = 0$ $^2 = 0.7598, p = 0$ $^2 = 0.7598, p = 0.06$ Events Total 7 8 35 35 12 12 8 9 12 14 15 17 31 32 28 28 $^2 = 0.4148, p = 0$ 155		Proportion 0.333 0.700 0.500 0.750 0.077 0.111 0.500 0.500 0.411 0.411 Proportion 0.875 1.000 0.889 0.857 0.882 0.969 1.000 0.957	95%-Cl [0.099; 0.651] [0.348; 0.933] [0.118; 0.882] [0.002; 0.360] [0.002; 0.360] [0.002; 0.360] [0.272; 0.728] [0.272; 0.728] [0.242; 0.603] [0.242; 0.603] [0.242; 0.603] [0.242; 0.603] [0.242; 0.603] [0.242; 0.603] [0.242; 0.603] [0.242; 0.603] [0.275; 0.728] [0.375; 1.000] [0.895; 0.983] [0.895; 0.983]
C D	Study g = CT Eljamel 1995 Shetty 1998 Chan 2004 Algin 2010 Tahir 2011 Ragheb 2014 Bhatia 2020 Hablas 2022 Random effects model Heterogeneity: $l^2 = 59\%$ , $\tau^2$ Residual heterogeneity: $l^2$ Study g = CT Eljamel 1995 Shetty 1998 Chan 2004 Algin 2010 Tahir 2011 Ragheb 2014 Bhatia 2020 Hablas 2022 Random effects model Heterogeneity: $l^2 = 28\%$ , $\tau^2$ Random effects model Heterogeneity: $l^2 = 28\%$ , $\tau^2$	Events Total 4 12 7 10 3 6 6 8 1 13 1 9 3 6 10 20 $^2 = 0.7598, p = 0$ $^2 = 0.7598, p = 0$ $^2 = 0.7598, p = 0.06$ Events Total 7 8 35 35 12 12 8 9 12 14 15 17 31 32 28 28 $^2 = 0.4148, p = 0$ $^2 = 0.4148, p = 0$		Proportion 0.333 0.700 0.500 0.770 0.111 0.500 0.411 0.411 Proportion 0.875 1.000 0.889 0.857 0.882 0.969 1.000 0.957 0.957	95%-Cl [0.099; 0.651] [0.348; 0.933] [0.118; 0.882] [0.002; 0.360] [0.002; 0.360] [0.002; 0.360] [0.272; 0.728] [0.272; 0.728] [0.242; 0.603] [0.242; 0.982] [0.242; 0.983] [0.242; 0.983] [0.242; 0.983]

**Figure 4.** Forest plots of sensitivity (**A**), specificity (**B**), negative predictive value (**C**) and positive predictive value (**D**) [2,11–17].

## 4. Discussion

HRCT showed a good diagnostic accuracy for CSF rhinorrhea, with a sensitivity of 75.5% and specificity of 85%. HRCT has a number of advantages: it can be performed easily and quickly, and is noninvasive and relatively inexpensive. In addition, as well as skull base bone dehiscence, overall facial bone damage can be assessed.

MRI is useful for determining mucosal pathology, but has the disadvantages of low resolution and difficulty in identifying bony structures. Therefore, a method using HRCT and MRI simultaneously was proposed [21]; however, there is an opinion that it is not effective in terms of cost-effectiveness [6]. Therefore, HRCT was preferred as a standalone diagnostic modality in several studies [4–6]. CT and radionuclide cisternography are advantageous for identifying leakage points. However, these methods are invasive because they require the intrathecal administration of a contrast agent through lumbar puncture, and the risk of morbidity associated with the contrast agent must be taken into consideration [22,23]. In other words, these methods have limitations as initial diagnostic tools. Magnetic resonance cisternography has the advantage of requiring no intrathecal contrast agent injection, and T2-weighted images with high signal intensity can be helpful for localizing CSF leakage points [24]. However, the lack of information on bony structures and the high cost (more than five times higher than HRCT) reduce the attractiveness of magnetic resonance cisternography for initial leakage point localization [6]. Recently, in addition to imaging tools, studies have been reported that can effectively check the CSF leak site using an endoscope equipped with a blue light filter after intrathecal fluorescein administration, increasing the number of options for diagnostic testing [24].

Taking the above points into account, HRCT has advantages as an initial diagnostic tool. However, the sensitivity of HRCT (75.5%) is disadvantageous in terms of its use as a screening tool. CT can provide indirect information about CSF fistula formation, but cannot be used to directly confirm leakage [25]. In addition, basilar defects of <2 mm are difficult to discriminate using HRCT. If the bone is thin due to mucocele, meningocele, or sinusitis, or if bone signals overlap, it may be difficult to determine the leakage point. Moreover, even in cases with multiple skull base fractures, there are limits to the accuracy of leakage point localization. As the sensitivity is low, a diagnosis should also be based on clinical symptoms and confirmatory tests [25,26].

Our meta-analysis had several limitations. First, differences in the quality of imaging equipment and imaging techniques among institutions may have affected diagnostic accuracy. Second, differences in image reading proficiency among clinicians may have affected the results. Therefore, care should be taken when interpreting the clinical results. Finally, most studies did not describe the etiology of CSF rhinorrhea, and did not determine whether the leaks were active or inactive.

### 5. Conclusions

This meta-analysis showed that HRCT is useful for localizing CSF rhinorrhea. However, given its limitations, HRCT should be combined with other tests for diagnostic confirmation as necessary.

**Author Contributions:** D.H.K., study conception and design, acquisition of data, analysis and interpretation of data, drafting the article and revisions, final approval of article; S.W.K., study conception and design, analysis and interpretation of data, drafting the article and revisions, final approval of article; J.S.H., acquisition of data, analysis and interpretation of data, drafting the article and revisions, final approval of article; G.-J.K., acquisition of data, analysis and interpretation of data, drafting the article and revisions, final approval of article; M.A.B., analysis and interpretation of data, drafting the article and revisions, final approval of article; S.H.H., study conception and design, acquisition of data, analysis and interpretation of data, drafting the article and revisions, final approval of article; S.H.H., study conception and design, acquisition of data, analysis and interpretation of data, drafting the article and revisions, final approval of article; S.H.H., study conception and design, acquisition of data, analysis and interpretation of data, drafting the article and revisions, final approval of article; S.H.H., study conception and design, acquisition of data, analysis and interpretation of data, drafting the article and revisions, final approval of article; S.H.H., study conception and design, acquisition of data, analysis and interpretation of data, drafting the article and revisions, final approval of artic

**Funding:** This work was supported by the National Research Foundation of Korea (NRF) (2022R1F1A1066232, 2019M3A9H2032424, 2020R1I1A1A01051844), Alchemist Project 1415180884 by the Ministry of Trade, Industry & Energy (MOTIE, Korea) (20012378), and the Institute of Clinical Medicine Research of Bucheon St. Mary's Hospital, Research Fund (2022). The sponsors had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Institutional Review Board Statement:** An ethics statement is not applicable because this study is based exclusively on published literature.

**Informed Consent Statement:** Informed consents were not required because this study is based exclusively on published literature.

**Data Availability Statement:** The raw data of individual articles used in this meta-analysis are included in the main text.

Conflicts of Interest: The authors declare no conflict of interest.

## References

- 1. Bullock, R.; Soares, D. Current imaging of cerebrospinal fluid leaks. W. Indian Med. J. 2009, 58, 362–366. [PubMed]
- Shetty, P.G.; Shroff, M.M.; Sahani, D.V.; Kirtane, M.V. Evaluation of high-resolution CT and MR cisternography in the diagnosis of cerebrospinal fluid fistula. *AJNR Am. J. Neuroradiol.* 1998, 19, 633–639. [PubMed]
- Ziu, M.; Savage, J.G.; Jimenez, D.F. Diagnosis and treatment of cerebrospinal fluid rhinorrhea following accidental traumatic anterior skull base fractures. *Neurosurg. Focus* 2012, 32, E3. [CrossRef] [PubMed]
- 4. Meco, C.; Oberascher, G. Comprehensive algorithm for skull base dural lesion and cerebrospinal fluid fistula diagnosis. *Laryngoscope* **2004**, *114*, 991–999. [CrossRef] [PubMed]
- 5. Oakley, G.M.; Alt, J.A.; Schlosser, R.J.; Harvey, R.J.; Orlandi, R.R. Diagnosis of cerebrospinal fluid rhinorrhea: An evidence-based review with recommendations. *Int. Forum Allergy Rhinol.* **2016**, *6*, 8–16. [CrossRef] [PubMed]
- 6. Pool, C.D.; Patel, V.A.; Schilling, A.; Hollenbeak, C.; Goyal, N. Economic implications of localization strategies for cerebrospinal fluid rhinorrhea. *Int. Forum Allergy Rhinol.* **2020**, *10*, 419–425. [CrossRef]
- 7. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. *BMJ* 2009, 339, b2535. [CrossRef]
- 8. Kim, D.H.; Kim, S.W.; Basurrah, M.A.; Hwang, S.H. Clinical and Laboratory Features of Various Criteria of Eosinophilic Chronic Rhinosinusitis: A Systematic Review and Meta-Analysis. *Clin. Exp. Otorhinolaryngol.* **2022**, *15*, 230–246. [CrossRef]
- 9. Hwang, S.H.; Kim, J.-S.; Choi, B.Y.; Kim, J.K.; Kim, B.G. Practical Review of Olfactory Training and COVID-19. J. Rhinol. 2022, 29, 127–133. [CrossRef]
- 10. Hwang, S.H.; Kim, S.W.; Basurrah, M.A.; Kim, D.H. Efficacy of steroid-impregnated spacers after endoscopic sinus surgery in chronic rhinosinusitis: A systematic review and meta-analysis. *Clin. Exp. Otorhinolaryngol.* 2023, *online ahead of print.* [CrossRef]
- 11. Eljamel, M.S.; Pidgeon, C.N. Localization of inactive cerebrospinal fluid fistulas. J. Neurosurg. 1995, 83, 795–798. [CrossRef]
- Chan, D.T.; Poon, W.S.; Ip, C.P.; Chiu, P.W.; Goh, K.Y. How useful is glucose detection in diagnosing cerebrospinal fluid leak? The rational use of CT and Beta-2 transferrin assay in detection of cerebrospinal fluid fistula. *Asian J. Surg.* 2004, 27, 39–42. [CrossRef] [PubMed]
- Algin, O.; Hakyemez, B.; Gokalp, G.; Ozcan, T.; Korfali, E.; Parlak, M. The contribution of 3D-CISS and contrast-enhanced MR cisternography in detecting cerebrospinal fluid leak in patients with rhinorrhoea. *Br. J. Radiol.* 2010, *83*, 225–232. [CrossRef] [PubMed]
- 14. Ragheb, A.S.; Mohammed, F.F.; El-Anwar, M.W. Cerebrospinal fluid rhinorrhea: Diagnostic role of gadolinium enhanced MR cisternography. *Egypt. J. Radiol. Nucl. Med.* 2014, 45, 841–847. [CrossRef]
- 15. Tahir, M.Z.; Khan, M.B.; Bashir, M.U.; Akhtar, S.; Bari, E. Cerebrospinal fluid rhinorrhea: An institutional perspective from Pakistan. *Surg. Neurol. Int.* **2011**, *2*, 174. [CrossRef] [PubMed]
- 16. Bhatia, D.; Murthy, D.N. Comparative retrospective study of HRCT, CT Cisternography and MRI in evaluation of CSF Leak. *Medicine* **2020**, *1008*, 7–12.
- 17. Hablas, L.T.; Ammar, A.M.; Elnagar, R.M. CSF rhinorrhea: Non-contrast CT, contrast-enhanced CT cisternography or combined? *Egypt. J. Radiol. Nucl. Med.* **2022**, *53*, 201. [CrossRef]
- 18. Reitsma, J.B.; Glas, A.S.; Rutjes, A.W.; Scholten, R.J.; Bossuyt, P.M.; Zwinderman, A.H. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. *J. Clin. Epidemiol.* **2005**, *58*, 982–990. [CrossRef]
- 19. Hoeboer, S.H.; van der Geest, P.J.; Nieboer, D.; Groeneveld, A.B. The diagnostic accuracy of procalcitonin for bacteraemia: A systematic review and meta-analysis. *Clin. Microbiol. Infect.* **2015**, *21*, 474–481. [CrossRef]
- Whiting, P.F.; Rutjes, A.W.; Westwood, M.E.; Mallett, S.; Deeks, J.J.; Reitsma, J.B.; Leeflang, M.M.; Sterne, J.A.; Bossuyt, P.M. QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies. *Ann. Intern. Med.* 2011, 155, 529–536. [CrossRef]
- Eljazzar, R.; Loewenstern, J.; Dai, J.B.; Shrivastava, R.K.; Iloreta, A.M., Jr. Detection of Cerebrospinal Fluid Leaks: Is There a Radiologic Standard of Care? A Systematic Review. World Neurosurg. 2019, 127, 307–315. [CrossRef]
- Goel, G.; Ravishankar, S.; Jayakumar, P.N.; Vasudev, M.K.; Shivshankar, J.J.; Rose, D.; Anandh, B. Intrathecal gadolinium-enhanced magnetic resonance cisternography in cerebrospinal fluid rhinorrhea: Road ahead? *J. Neurotrauma* 2007, 24, 1570–1575. [CrossRef] [PubMed]
- 23. Kojima, A.; Matsumoto, M.; Tomiguchi, S.; Katsuda, N.; Yamashita, Y.; Motomura, N. Accurate scatter correction for transmission computed tomography using an uncollimated line array source. *Ann. Nucl. Med.* **2004**, *18*, 45–50. [CrossRef] [PubMed]
- 24. Edora, B.D.; Chua, R.; Estolano, P.J. A Makeshift Blue Light Filter for Endoscopic Identification of Traumatic Cerebrospinal Fluid Leak Using Fluorescein. *Philipp. J. Otolaryngol. Head Neck Surg.* **2022**, *37*, 46. [CrossRef]

- 25. El Gammal, T.; Sobol, W.; Wadlington, V.R.; Sillers, M.J.; Crews, C.; Fisher, W.S., 3rd; Lee, J.Y. Cerebrospinal fluid fistula: Detection with MR cisternography. *AJNR Am. J. Neuroradiol.* **1998**, *19*, 627–631.
- 26. Mostafa, B.E.; Khafagi, A. Combined HRCT and MRI in the detection of CSF rhinorrhea. *Skull Base* **2004**, *14*, 157–162; discussion 162. [CrossRef]

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.